Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression

Oncogene

Volumn 32, Issue 34, 2013, Pages 3933-3943

  Hu, Q ^a   Lu, Y Y ^b   Noh, H ^a   Hong, S ^a   Dong, Z ^a   Ding, H F ^a   Su, S B ^b   Huang, S ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

ILF3; miRNA; Transcription; uPA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; INTERLEUKIN ENHANCER BINDING FACTOR 3; MESSENGER RNA; MICRORNA; PROGESTERONE RECEPTOR; PROTEIN C JUN; SMALL INTERFERING RNA; STAT1 PROTEIN; TRANSCRIPTION FACTOR ETS 1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR INVASION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MICRORNAS; NUCLEAR FACTOR 90 PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84883161066     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.414     Document Type: Article

References (46)

1. Blasi F. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system. Thromb Haemost 1999; 82: 298-304.
2. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 932-943.
3. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-135.
4. Annecke K, Schmitt M, Euler U, Zerm M, Paepke D, Paepke S et al. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Adv Clin Chem 2008; 45: 31-45.
5. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F et al. Urokinase-type plasminogen activator and its inhibitor type predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 2004; 5: 348-352.
6. Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 2001; 61: 400-405.
7. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001; 61: 1367-1374.
8. Johnson MD, Torri JA, Lippman ME, Dickson RB. Regulation of motility and protease expression in PKC-mediated induction of MCF-7 breast cancer cell invasiveness. Exp Cell Res 1999; 247: 105-113.
9. Crippa MP. Urokinase-type plasminogen activator. Int J Biochem Cell Biol 2007; 39: 690-694.
10. Mahanivong C, Yu J, Huang S. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator. Mol Carcinog 2007; 46: 165-175.
11. Noh H, Hong S, Dong Z, Pan ZK, Jing Q, Huang S. Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer 2011; 2: 140-150.
12. Aguirre Ghiso JA, Alonso DF, Farias EF, Gomez DE, de Kier Joffe EB. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. Eur J Biochem 1999; 263: 295-304.
13. Kao PN, Chen L, Brock G, Ng J, Kenny J, Smith AJ et al. Cloning and expression of cyclosporin A-and FK506-sensitive nuclear factor of activated T-cells: NF45 and NF90. J Biol Chem 1994; 269: 20691-20699.
14. Corthesy B, Kao PN. Purification by DNA affinity chromatography of two polypeptides that contact the NF-AT DNA binding site in the interleukin 2 promoter. J Biol Chem 1994; 269: 20682-20690.
15. Shi L, Godfrey WR, Lin J, Zhao G, Kao PN. NF90 regulates inducible IL-2 gene expression in T cells. J Exp Med 2007; 204: 971-977.
16. Duchange N, Pidoux J, Camus E, Sauvaget D. Alternative splicing in the human interleukin enhancer binding factor 3 (ILF3) gene. Gene 2000; 261: 345-353.
17. Reichman TW, Parrott AM, Fierro-Monti I, Caron DJ, Kao PN, Lee CG et al. Selective regulation of gene expression by nuclear factor 110, a member of the NF90 family of double-stranded RNA-binding proteins. J Mol Biol 2003; 332: 85-98.
18. Kiesler P, Haynes PA, Shi L, Kao PN, Wysocki VH, Vercelli D. NF45 and NF90 regulate HS4-dependent interleukin-13 transcription in T cells. J Biol Chem 2010; 285: 8256-8267.
19. Kuwano Y, Kim HH, Abdelmohsen K, Pullmann Jr R, Martindale JL, Yang X et al. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol 2008; 28: 4562-4575.
20. Kuwano Y, Pullmann Jr R, Marasa BS, Abdelmohsen K, Lee EK, Yang X et al. NF90 selectively represses the translation of target mRNAs bearing an AU-rich signature motif. Nucleic Acids Res 2010; 38: 225-238.
21. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol 2008; 28: 772-783.
22. Pei Y, Zhu P, Dang Y, Wu J, Yang X, Wan B et al. Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation. J Immunol 2008; 180: 222-229.
23. Sakamoto S, Aoki K, Higuchi T, Todaka H, Morisawa K, Tamaki N et al. The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol 2009; 29: 3754-3769.
24. Fung LF, Lo AK, Yuen PW, Liu Y, Wang XH, Tsao SW. Differential gene expression in nasopharyngeal carcinoma cells. Life Sci 2000; 67: 923-936.
25. Guo NL, Wan YW, Tosun K, Lin H, Msiska Z, Flynn DC et al. Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 2008; 14: 8213-8220.
26. Guo Y, Fu P, Zhu H, Reed E, Remick SC, Petros W et al. Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by ovarian cancer. Oncol Rep 2012; 27: 286-292.
27. Guan D, Altan-Bonnet N, Parrott AM, Arrigo CJ, Li Q, Khaleduzzaman M et al. Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control. Mol Cell Biol 2008; 28: 4629-4641.
28. Price JE, Polyzos A, Zhang RD, Daniels LM. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-721.
29. Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res 1999; 59: 5041-5046.
30. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-643.
31. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-136.
32. Almholt K, Lund LR, Rygaard J, Nielsen BS, Dano K, Romer J et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005; 113: 525-532.
33. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H et al. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 1998; 77: 128-137.
34. Sliva D, English D, Lyons D, Lloyd Jr FP.Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 2002; 290: 552-557.
35. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003; 278: 28593-28606.
36. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 2004; 279: 11051-11064.
37. Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK et al. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 2009; 69: 9228-9235.
38. Amorino GP, Hamilton VM, Valerie K, Dent P, Lammering G, Schmidt-Ullrich RK. Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 2002; 13: 2233-2244.
39. Vanden BW, Dijsselbloem N, Vermeulen L, Ndlovu MN, Boone E, Haegeman G. Attenuation of mitogen-and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 2006; 66: 4852-4862.
40. Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK et al. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells. J Biol Chem 2002; 277: 48379-48385.
41. Li H, Ye X, Mahanivong C, Bian D, Chun J, Huang S. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 2005; 280: 10564-10571.
42. Mahanivong C, Chen HM, Yee SW, Pan ZK, Dong Z, Huang S. Protein kinase Calpha-CARMA3 signaling axis links Ras to NF-kappaB for lysophosphatidic acidinduced urokinase plasminogen activator expression in ovarian cancer cells. Oncogene 2008; 27: 1273-1280.
43. Huang S, Chakrabarty S. Expression of antisense fibronectin RNA in human colon carcinoma cells disrupts the regulation of carcinoembryonic antigen by transforming growth factor beta 1. J Biol Chem 1994; 269: 28764-28768.
44. Li Y, Kimura T, Huyck RW, Laity JH, Andrews GK. Zinc-induced formation of a coactivator complex containing the zinc-sensing transcription factor MTF-1, p300/CBP, and Sp1. Mol Cell Biol 2008; 28: 4275-4284.
45. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN et al. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene 2009; 28: 3047-3057.
46. McCarty Jr KS,Miller LS, Cox EB, Konrath J, McCarty Sr KS.Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109: 716-721.